Cargando…

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir

Dasabuvir, a nonnucleoside NS5B polymerase inhibitor, is a sensitive substrate of cytochrome P450 (CYP) 2C8 with a potential for drug–drug interaction (DDI) with clopidogrel. A physiologically based pharmacokinetic (PBPK) model was developed for dasabuvir to evaluate the DDI potential with clopidogr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shebley, M, Fu, W, Badri, P, Bow, DAJ, Fischer, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599937/ https://www.ncbi.nlm.nih.gov/pubmed/28411400 http://dx.doi.org/10.1002/cpt.689

Ejemplares similares

Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?
por: Shebley, Mohamad
Publicado: (2018)

Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel
por: Itkonen, Matti K., et al.
Publicado: (2018)

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Chiney, Manoj S., et al.
Publicado: (2019)

Response to “Quantitative Prediction of Drug‐Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?”
por: Templeton, IE, et al.
Publicado: (2017)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?
por: Templeton, IE, et al.
Publicado: (2016)

Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir
por: Badri, P., et al.
Publicado: (2015)

Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy
por: Wang, Zhi-Yu, et al.
Publicado: (2015)

"Influence of methadone on clopidogrel in addicts on methadone maintenance therapy" Drug interaction between methadone and clopidogrel
por: Fallah, Ferigol, et al.
Publicado: (2016)

Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers
por: Polepally, Akshanth R., et al.
Publicado: (2016)

Development and validation of UPLC-MS/MS method for studying the pharmacokinetic interaction of dasabuvir and tamoxifen, 4-hydroxytamoxifen in Wistar rats
por: Almomen, Aliyah, et al.
Publicado: (2020)

Evaluation of a Clinically Relevant Drug–Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity
por: Ning, Chen, et al.
Publicado: (2021)

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells
por: Stefanik, Michal, et al.
Publicado: (2020)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

2535. Physiological-based pharmacokinetic analysis of drug–drug interactions between isavuconazole and vincristine in pediatric subjects
por: Choules, Mary P, et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug–Drug Interactions
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
por: Hanke, Nina, et al.
Publicado: (2021)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
por: Chen, Yuan, et al.
Publicado: (2020)

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
por: Choi, Min-Koo, et al.
Publicado: (2021)

Prediction of Drug–Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
por: Ji, Beihong, et al.
Publicado: (2019)

Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
por: Wei, Zhuodu, et al.
Publicado: (2023)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
por: Min, Jee Sun, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions
por: Britz, Hannah, et al.
Publicado: (2020)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
por: Yu, Zhiheng, et al.
Publicado: (2022)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
por: Wu, Fan, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling Framework for Quantitative Prediction of an Herb–Drug Interaction
por: Brantley, S J, et al.
Publicado: (2014)

A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors
por: Cressman, Alex M, et al.
Publicado: (2015)

Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants
por: Salerno, Sara N., et al.
Publicado: (2020)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

Pharmacokinetic Drug-Drug Interaction and Responsible Mechanism between Memantine and Cimetidine
por: Choi, Young A., et al.
Publicado: (2018)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
por: Tod, M, et al.
Publicado: (2017)

Investigating Transporter‐Mediated Drug‐Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin
por: Wang, Q, et al.
Publicado: (2017)

Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach
por: Schaller, Stephan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uqrv93l57v52f80gabep7hckj8